A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population based on biomarkers. Experimental Design: This was a randomized, double-blind, placebo-controlled, phase II study. Patients were randomly assigned in a 2:1 ratio to receive weekly intravenous ontuxizumab (8 mg/kg) or placebo plus best supportive care until progression or unacceptable toxicity. Tissue and blood biomarkers were evaluated for their ability to identify a patient population that was responsive to ontuxizumab. Results: A total of 126 patients were enrolled. No significant difference between the ontuxizumab and placebo groups was evident for the primary endpoint of progression-free survival (PFS), with a median PFS of 8.1 weeks in each group (HR, 1.13; 95% confidence interval, 0.76–1.67; P = 0.53). There were no significant differences between groups for overall survival (OS) or overall response rate (ORR). The most common treatment-emergent adverse events (TEAEs) in the ontuxizumab group (vs. the placebo group, respectively) were fatigue (53.7% vs. 47.5%), nausea (39.0% vs. 35.0%), decreased appetite (34.1% vs. 27.5%), and constipation (28.0% vs. 32.5%). The most common grade 3/4 TEAE in the ontuxizumab group versus placebo was back pain (11.0% vs. 0%). No single biomarker clearly identified patients responsive to ontuxizumab. Conclusions: No benefit with ontuxizumab monotherapy compared with placebo for clinical response parameters of PFS, OS, or ORR was demonstrated. Ontuxizumab was well tolerated. Clin Cancer Res; 24(2); 316–25. ©2017 AACR.

[1]  K. Furuuchi,et al.  Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature , 2015, Oncotarget.

[2]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[3]  W. Jiang,et al.  Prognostic values of tumor endothelial markers in patients with colorectal cancer. , 2005, World journal of gastroenterology.

[4]  K. Kinzler,et al.  Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Oberoi,et al.  Novel antibody probes for the characterization of endosialin/TEM-1 , 2016, Oncotarget.

[6]  Ron Brookmeyer,et al.  A Confidence Interval for the Median Survival Time , 1982 .

[7]  Nicolas C. Nicolaides,et al.  Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling , 2010, Cancer biology & therapy.

[8]  H. Dai,et al.  Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies , 2016, Sarcoma.

[9]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[10]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Coukos,et al.  Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model , 2014, Cancer biology & therapy.

[12]  N. Kraut,et al.  Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. , 2005, Cancer immunity.

[13]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[14]  B. Teicher,et al.  Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies , 2015, Molecular Cancer Therapeutics.

[15]  Daniel J Sargent,et al.  Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. , 2014, Chinese clinical oncology.

[16]  B. Foley,et al.  Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration , 2007, Proceedings of the National Academy of Sciences.

[17]  L. Diaz,et al.  A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[18]  Hong Zhang,et al.  Endosialin expression in relation to clinicopathological and biological variables in rectal cancers with a Swedish clinical trial of preoperative radiotherapy , 2011, BMC Cancer.

[19]  D. Dimitrov,et al.  Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. , 2017, Cancer cell.

[20]  Rebecca L. Siegel Mph,et al.  Colorectal cancer statistics, 2014 , 2014 .

[21]  Ilya Lipkovich,et al.  Strategies for Identifying Predictive Biomarkers and Subgroups with Enhanced Treatment Effect in Clinical Trials Using SIDES , 2014, Journal of biopharmaceutical statistics.

[22]  S. Seaman,et al.  Genes that distinguish physiological and pathological angiogenesis. , 2007, Cancer cell.

[23]  I. Lipkovich,et al.  Subgroup identification based on differential effect search—A recursive partitioning method for establishing response to treatment in patient subpopulations , 2011, Statistics in medicine.

[24]  J. Healey,et al.  Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Bordeaux,et al.  Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins , 2014, Oncotarget.

[26]  Ł. Pietrzyk.  Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates , 2016, Disease markers.

[27]  D. Schadendorf,et al.  Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. , 2008, The American journal of pathology.

[28]  B. Teicher,et al.  Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma , 2008, Clinical Cancer Research.

[29]  P. Gasque,et al.  Human Endosialin (Tumor Endothelial Marker 1) Is Abundantly Expressed in Highly Malignant and Invasive Brain Tumors , 2004, Journal of neuropathology and experimental neurology.

[30]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[31]  G. G. Van den Eynden,et al.  Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases , 2016, Nature Medicine.

[32]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[33]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.